清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 5144: BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumors: Design of bicyclic peptide and linker selection

噬菌体展示 连接器 肽 双环分子 蛋白酶 结合 生物化学 化学 组合化学 肽库 计算生物学 生物 酶 肽序列 基因 立体化学 操作系统 数学分析 计算机科学 数学
作者
Helen Harrison,Gavin Bennett,D M Blakeley,Amy Brown,Spencer Campbell,Liuhong Chen,Robert J. Lutz,Silvia Pavan,Katerine Van Rietschoten,Daniel Teufel,Peter U. Park,Kevin Lee
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (13_Supplement): 5144-5144 被引量:7
标识
DOI:10.1158/1538-7445.am2017-5144
摘要

Abstract Bicycles® are novel binding agents comprising small bicyclic peptides (1.5-3 KDa) constrained via a chemical scaffold, selected for high affinity and selectivity to targets of interest. MT1 (MMP14/MT1-MMP) is a membrane-associated metalloprotease overexpressed in many solid tumours and is implicated in tumor invasion and metastasis. MT1 expression positively correlates with poor prognosis. Phage libraries containing 1015 unique peptide sequences were post-translationally cyclized with thiol-reactive scaffold and used in an optimized, high-throughput selection process to identify Bicycles® to the hemopexin domain of MT1. Additional iterative rounds of directed phage based screening were used to optimize affinity and off-phage non-natural amino acids were introduced at select positions to improve plasma stability to generate the lead Bicycle binder. The lead anti-MT1 Bicycle was further modified with a sarcosyl spacer to form N241. N241 binds specifically to the hemopexin domain of MT1 with a Kd of approximately 2 nM with no binding observed to the catalytic domain of the protease nor to any of the related MMP family members tested. Importantly and in contrast to most antibodies, N241 binds with similar affinity to MT1 from multiple species including rodent, dog and non-human primate. Since the expected rapid tumor penetration and specific binding of these small peptidyl-binders makes them ideal for use in targeted delivery approaches, a series of Bicycle drug conjugates (BDCs) were prepared; N241 was conjugated to potent maytansinoid cytotoxics via linkers which varied in their cleavability. Though all the BDCs maintained high affinity for MT1, efficacy toward MT1-positive human tumor mouse xenografts varied with linker stability. BDCs with the most stable linkers were the least active suggesting that optimal tumor activation was obtained with linkers that could be cleaved more rapidly. Due to the rapid clearance and limited systemic exposure of these small-targeting BDCs, only the most labile linker showed toxicity in the mouse studies. Of the BDCs tested, BT1718, composed of N241 and DM1 conjugated via the SPP linker, demonstrated an optimal therapeutic index. Potent anti-tumor efficacy with BT1718 was observed across a panel of MT1-positive xenografts with complete tumor regressions observed in most models at doses that were well tolerated. In one example, HT-1080 fibrosarcoma subcutaneous xenografts were intraveneously treated with BT1718 when the tumor size had reached approximately 180 mm3. BT1718 given at 3 mg/kg once a week resulted in tumor stasis while BT1718 given at 10 mg/kg once a week or 3 mg/kg twice a week induced complete regression. In summary, BT1718, a highly active, targeted drug conjugate with unique pharmacological properties is a promising therapeutic candidate for the treatment of MT1-MMP-positive solid tumors. Citation Format: Helen Harrison, Gavin Bennett, Diane Blakeley, Amy Brown, Spencer Campbell, Liuhong Chen, Robert J. Lutz, Silvia Pavan, Katerine van Rietschoten, Daniel Teufel, Peter U. Park, Kevin Lee. BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumors: Design of bicyclic peptide and linker selection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5144. doi:10.1158/1538-7445.AM2017-5144
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
12秒前
whuhustwit完成签到,获得积分10
23秒前
27秒前
欣心发布了新的文献求助10
31秒前
明亮的依珊完成签到,获得积分10
54秒前
55秒前
n01W97的应助被念姬采纳,获得20
57秒前
兴奋筮完成签到,获得积分10
1分钟前
1分钟前
余又完成签到 ,获得积分10
1分钟前
科研通AI6.3的应助被RZH采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
感动的天德完成签到,获得积分10
1分钟前
清脆的芒果完成签到,获得积分10
1分钟前
lishuhua完成签到 ,获得积分10
1分钟前
2分钟前
2分钟前
nikki完成签到 ,获得积分10
2分钟前
2分钟前
CZLhaust发布了新的文献求助10
2分钟前
CZLhaust发布了新的文献求助10
2分钟前
CZLhaust发布了新的文献求助10
2分钟前
CZLhaust发布了新的文献求助10
2分钟前
CZLhaust发布了新的文献求助10
2分钟前
RZH发布了新的文献求助10
2分钟前
2分钟前
漂亮的又槐完成签到,获得积分10
2分钟前
syvshc的应助被兰斯洛特117采纳,获得10
2分钟前
nav完成签到 ,获得积分10
2分钟前
Lucas的应助被王泰一采纳,获得10
2分钟前
2分钟前
sissiarno完成签到,获得积分0
2分钟前
文静文静666完成签到,获得积分10
2分钟前
Ruby于完成签到 ,获得积分10
2分钟前
RYYYYYYY233完成签到 ,获得积分0
2分钟前
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173225
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780511
捐赠科研通 7767377
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555750
邀请新用户注册赠送积分活动 2476697